Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lowered its position in Exact Sciences Co. (NASDAQ:EXAS) by 1.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,320 shares of the medical research company’s stock after selling 651 shares during the period. Victory Capital Management Inc.’s holdings in Exact Sciences were worth $2,322,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Thompson Investment Management Inc. grew its holdings in Exact Sciences by 17.8% during the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock valued at $13,585,000 after buying an additional 36,505 shares during the last quarter. Zacks Investment Management acquired a new stake in Exact Sciences during the 3rd quarter valued at $2,083,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Exact Sciences by 59.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock valued at $22,868,000 after buying an additional 125,192 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Exact Sciences by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after buying an additional 45,015 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its holdings in Exact Sciences by 35.3% during the 4th quarter. Harbor Capital Advisors Inc. now owns 95,827 shares of the medical research company’s stock valued at $5,385,000 after buying an additional 24,992 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

EXAS has been the topic of several analyst reports. Bank of America decreased their price objective on Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, February 20th. Benchmark restated a “buy” rating and set a $65.00 price objective on shares of Exact Sciences in a report on Monday, January 13th. BTIG Research raised their price objective on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Scotiabank raised their price objective on Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Finally, Barclays decreased their price objective on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Two analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $70.83.

Exact Sciences Trading Up 0.4 %

NASDAQ:EXAS opened at $45.18 on Tuesday. The business’s 50-day moving average is $51.48 and its two-hundred day moving average is $58.70. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The firm has a market capitalization of $8.39 billion, a PE ratio of -8.11 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Research analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.